UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January ~~December~~ 12, ~~2025~~2026

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On ~~December~~January 12, ~~2025~~2026, Emergent ~~BioSolutions~~Biosolutions, Inc., a Delaware corporation (the “Company”), ~~issued~~announced that it made a ~~press~~voluntary ~~release~~prepayment ~~regarding~~of ~~the~~$100 ~~Company’s~~million ~~receipt~~in oflate ~~U.S.~~December ~~Food~~2025 ~~and~~under ~~Drug~~its ~~Administration~~outstanding ~~approval~~term ~~for~~loan ~~drug~~(the ~~product~~“Term ~~manufacturing~~Loan”), ofunder ~~raxibacumab~~that atcertain ~~the~~Credit ~~Company’s~~Agreement ~~Winnipeg~~dated ~~manufacturing~~as ~~site~~of August 30, a2024, ~~copy~~by ofand ~~which~~among isthe ~~furnished~~Company, asthe ~~Exhibit~~lenders ~~99.1~~from time to ~~this~~time ~~Current~~party ~~Report~~thereto onand ~~Form~~OHA ~~8-K.~~Agency LLC, as administrative agent.

A copy of the press release on January 12, 2026, announcing the Company’s prepayment of the Term Loan is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release issued by Emergent BioSolutions Inc. on ~~December~~January 12, ~~2025~~2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EMERGENT BIOSOLUTIONS INC.
Dated: December 12, 2025	By:	/s/ RICHARD S. LINDAHL
Dated: January12, 2026	By:	/s/ RICHARD S. LINDAHL
		Name: Richard S. LindahlTitle: Executive Vice President, Chief Financial Officer and Treasurer

Filing Compare · Emergent BioSolutions Inc.